Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$5.03+0.07 (+1.41%)
Close on Nov 18, 2026Market cap $195.85MP/E –Yield –
Entrada Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Entrada Therapeutics's pe ratio was 7.3× on Jul 31, 2025, against 27.9× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jul 31, 2025 | 7.3× | −3.9 |
| 2024 | Dec 31, 2024 | 11.2× | – |
See a number that looks wrong?